Harvard Bioscience
HBIO
HBIO
98 hedge funds and large institutions have $187M invested in Harvard Bioscience in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 40 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
11% less capital invested
Capital invested by funds: $211M → $187M (-$24M)
33% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 40
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Holders
98
Holding in Top 10
2
Calls
$32K
Puts
$4K
Top Buyers
| 1 | +$5.97M | |
| 2 | +$1.85M | |
| 3 | +$1.81M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.36M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$601K |
Top Sellers
| 1 | -$3.05M | |
| 2 | -$1.25M | |
| 3 | -$1.08M | |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$824K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$806K |